Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
Open Access
- 1 March 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical and Translational Gastroenterology
- Vol. 12 (3), e00315
- https://doi.org/10.14309/ctg.0000000000000315
Abstract
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct inflammation and fibrosis. The role of macrophages in PSC development and progression is less studied. Macrophage activation markers soluble (s)CD163 and mannose receptor (sMR) are associated with disease severity and outcome in other liver diseases, but not previously investigated in PSC. We evaluated sCD163 and sMR regarding disease severity and prognosis in patients with PSC. METHODS: We investigated 2 independent PSC cohorts from Oslo (n = 138) and Helsinki (n = 159) and analyzed blood sCD163 and sMR levels. The Mayo score, Enhanced Liver Fibrosis Test, and Amsterdam-Oxford model were assessed for comparison. RESULTS: Median (interquartile range) sCD163 was 3.32 (2.27–5.60) and 1.96 (1.47–2.70) mg/L in the Oslo and Helsinki cohorts, respectively, reflecting differences in disease severity between cohorts. Median sMR was similar in both cohorts, 0.28 (0.22–0.44) and 0.28 mg/L (0.20–0.36), respectively. In both cohorts, sCD163 and sMR levels raised with increasing disease severity (liver enzymes, Mayo score, and enhanced liver fibrosis test). Patients with high baseline levels of sCD163 had shorter transplant-free survival than patients with low baseline levels. Furthermore, sCD163 was associated with transplant-free survival in univariate cox-regression analyses. Both sCD163 and sMR performed better in the Oslo cohort of more severely diseased patients than those in the Helsinki cohort of more mildly diseased patients. DISCUSSION: Macrophage activation markers are elevated according to disease severity suggesting an important role of macrophages in PSC. Furthermore, sCD163 was identified as a prognostic marker and predictor of transplant-free survival in PSC (see Visual Abstract, Supplementary Digital Content 4, http://links.lww.com/CTG/A516 ).Keywords
This publication has 41 references indexed in Scilit:
- The mannose receptorJournal of Leukocyte Biology, 2012
- Soluble CD163, a marker of Kupffer cell activation, is related to portal hypertension in patients with liver cirrhosisAlimentary Pharmacology & Therapeutics, 2012
- Soluble CD163Scandinavian Journal of Clinical and Laboratory Investigation, 2011
- Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPSGut, 2011
- Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issueJournal of Hepatology, 2010
- Diagnosis and management of primary sclerosing cholangitisJournal of Hepatology, 2009
- EASL Clinical Practice Guidelines: Management of cholestatic liver diseasesJournal of Hepatology, 2009
- A Revised Natural History Model for Primary Sclerosing CholangitisMayo Clinic Proceedings, 2000
- A Revised Natural History Model for Primary Sclerosing CholangitisMayo Clinic Proceedings, 2000
- Serum Levels of Interleukins 8 and 10, Interferon γ, Granulocyte-macrophage Colony Stimulating Factor and Soluble CD23 in Patients with Primary Sclerosing CholangitisAutoimmunity, 1997